Investing Profile

Gregory Harriman

InvestorVCAngel
Partner, Chief Investment Officer at BioAdvance
Photo of Gregory Harriman, Partner at BioAdvance
University of California, Berkeley Network
251 CONNECTIONS
Johnson & Johnson Network
17 CONNECTIONS
cb
BioAdvance Partner
$1.5M - $5.0M
$3.3M
3
CompanyStageDateRound SizeTotal Raised
Senzo
SeedDec 2022$2M
SeedJul 2022$2M
$4M
Co-investors: Arvind Gupta (Mayfield), Jay Zaveri (Social Capital), Luigi Bajetti (LombardStreet Ventures), Chris Sang (CP Ventures)
Opsidio
Series UnknownSep 2017$500K
$500K
Director Senzo Health2022 - Present
Partner, Chief Investment Officer BioAdvance2021 - Present
Director Opsidio, LLC2017 - Present
Director Treventis2012 - Present
President Main Line Ventures2006 - Present
Director RIBONOVA INC.2016 - 2021
Venture Partner BioAdvance2012 - 2021
Director Genome Profiling, LLC2017 - 2018
Director Enzium, Inc.2015 - 2017
Director Immunome2012 - 2017
Member Robin Hood Ventures2010 - 2017
Director QR Pharma2012 - 2014
Research Professor, School of Biomedical Engineering, Science and Health Systems Drexel University2010 - 2014
Director Novira Therapeutics2011 - 2012
Vice President Johnson & Johnson2001 - 2009
Executive Director Centocor1998 - 2001
Medical Director IVAX1996 - 1998
Assistant Professor of Medicine Baylor College of Medicine1991 - 1996
UC San Diego School of Medicine M.D. Medicine
University of California, Berkeley